Your browser doesn't support javascript.
loading
PF-05280014 (a trastuzumab biosimilar) plus paclitaxel compared with reference trastuzumab plus paclitaxel for HER2-positive metastatic breast cancer: a randomised, double-blind study.
Pegram, Mark D; Bondarenko, Igor; Zorzetto, Marina Moreira Costa; Hingmire, Sachin; Iwase, Hirotaka; Krivorotko, Petr V; Lee, Keun Seok; Li, Rubi K; Pikiel, Joanna; Aggarwal, Rajesh; Ewesuedo, Reginald; Freyman, Amy; Li, Ray; Vana, Alicia; Yin, Donghua; Zacharchuk, Charles; Tan-Chiu, Elizabeth.
Afiliación
  • Pegram MD; Stanford Comprehensive Cancer Institute, Stanford University School of Medicine, 900 Blake Wilbur, Stanford, CA, 94305, USA.
  • Bondarenko I; Oncology and Medical Radiology Department, Dnipropetrovsk Medical Academy, 31 Blyzhnya Street, Dnipro, 49102, Ukraine.
  • Zorzetto MMC; Department of Clinical Oncology, Barretos Cancer Hospital, Rua Antenor Duarte Villela, 1331 - Dr. Paulo Prata, Barretos, São Paulo, 14784-400, Brazil.
  • Hingmire S; Department of Oncology, Deenanath Mangeshkar Hospital and Research Centre, Erandawne, Pune, Maharashtra, 411004, India.
  • Iwase H; Department of Breast and Endocrine Surgery, Kumamoto University Graduate School of Medical Science, 1-1-1, Honjo, Chuo-ku, Kumamoto, 860-8556, Japan.
  • Krivorotko PV; Department of Breast Tumors, Petrov Research Institute of Oncology, 68 Leningradskaya Street, Pesochny, 197758, Saint Petersburg, Russian Federation.
  • Lee KS; Center for Breast Cancer, National Cancer Center, 323 Ilsan-ro, Ilsandong-gu, Goyang-si, Gyeonggi-do, Republic of Korea.
  • Li RK; Section of Medical Oncology, Cancer Institute, St. Luke's Medical Center, 279 E Rodriguez Sr. Ave, Quezon City, 1112, Metro Manila, Philippines.
  • Pikiel J; Copernicus, Wojewódzkie Centrum Onkologii, Al. Zwyciestwa 31/32, 80-210, Gdansk, Poland.
  • Aggarwal R; Pfizer Essential Health, Worldwide Safety, Pfizer Inc, 235 East 42nd Street, New York, NY, 10017, USA.
  • Ewesuedo R; Pfizer Essential Health, Biosimilars Clinical R&D, Pfizer Inc, 610 Main Street, Cambridge, MA, 02139, USA. reginald.ewesuedo@pfizer.com.
  • Freyman A; Pfizer Essential Health, Biosimilars Clinical R&D, Pfizer Inc, 610 Main Street, Cambridge, MA, 02139, USA.
  • Li R; Early Clinical Development Statistics, Pfizer Inc, 1 Portland Street, Cambridge, MA, 02139, USA.
  • Vana A; Pfizer Essential Health, Biosimilars Clinical R&D, Pfizer Inc, 10777 Science Center Drive, San Diego, CA, 92121, USA.
  • Yin D; Clinical Pharmacology, Pfizer Inc, 10777 Science Center Drive, San Diego, CA, 92121, USA.
  • Zacharchuk C; Pfizer Essential Health, Biosimilars Clinical R&D, Pfizer Inc, 610 Main Street, Cambridge, MA, 02139, USA.
  • Tan-Chiu E; Medical Oncology, Florida Cancer Research Institute, 201 NW 82nd Avenue, Suite 102, Plantation, FL, 33324, USA.
Br J Cancer ; 120(2): 172-182, 2019 01.
Article en En | MEDLINE | ID: mdl-30568294
Asunto(s)
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Neoplasias de la Mama / Receptor ErbB-2 / Anticuerpos Monoclonales Humanizados / Trastuzumab Tipo de estudio: Clinical_trials Límite: Adult / Aged / Aged80 / Female / Humans / Middle aged Idioma: En Revista: Br J Cancer Año: 2019 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: Reino Unido
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Neoplasias de la Mama / Receptor ErbB-2 / Anticuerpos Monoclonales Humanizados / Trastuzumab Tipo de estudio: Clinical_trials Límite: Adult / Aged / Aged80 / Female / Humans / Middle aged Idioma: En Revista: Br J Cancer Año: 2019 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: Reino Unido